Unacceptable Antibiotic Resistance Rates for Helicobacter pylori in Turkey: Something Must Change.

BACKGROUND It is known that clarithromycin resistance has increased over the years (success rate 60%). The aim of the study was to investigate the importance of regional antimicrobial resistance rates for full accuracy of both diagnosis and treatment of Helicobacter pylori infection. METHODS This study was carried out in the University Hospital Department of Gastroenterology. A total of 116 patients were evaluated with upper gastrointestinal endoscopy. Gastric antrum and corpus biopsy samples were taken for the rapid urease test (RUT), culture, and antimicrobial susceptibility testing for the presence of H. pylori. Antimicrobial susceptibilities of isolated H. pylori strains for clarithromycin and levofloxacin were determined by the epsilometer test (E-test). Minimal inhibitory concentration values for clarithromycin and levofloxacin were ≥1 and >1 μg/mL, respectively. RESULTS H. pylori infection was considered clinically positive in 93 (80.2%) patients with either the RUT, culture, or histopathological examination. Seventy (60.3%) of the patients had RUT positivity. Sixty (85.7%) of these 70 patients had RUT positivity within the first 20 min. Among the 90 patients, who had a histopathological examination, HLO was positive in 76 (84.4%) patients. Fifty-two (44.8%) out of 116 patients were culture positive. Resistance rates for both clarithromycin and levofloxacin were high. In these 52 culture-positive patients, resistance rates determined for clarithromycin and levofloxacin were 26.9% and 25.5%, respectively. CONCLUSION Clarithromycin or levofloxacin-based treatment regimen may not be an ideal alternative therapy for Turkish patients regardless of culture.

[1]  M. Topbaş,et al.  Sociodemographic characteristics and clinical risk factors of Helicobacter pylori infection and antibiotic resistance in the Eastern Black Sea region of Turkey. , 2020, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[2]  A. Tanoğlu,et al.  Helicobacter pylori treatment in Turkey: Current status and rational treatment options , 2019, Northern clinics of Istanbul.

[3]  A. Kanık,et al.  Standard triple therapy in Helicobacter pylori eradication in Turkey: Systematic evaluation and meta-analysis of 10-year studies. , 2019, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[4]  D. Graham,et al.  Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. , 2018, Gastroenterology.

[5]  A. Zullo,et al.  Antibiotic resistance pattern of Helicobacter pylori strains isolated in Italy during 2010–2016 , 2018, Scandinavian journal of gastroenterology.

[6]  A. Babazadeh,et al.  Diagnostic methods for Helicobacter pylori infection: ideals, options, and limitations , 2018, European Journal of Clinical Microbiology & Infectious Diseases.

[7]  J. Gisbert,et al.  Accuracy of the Ultra-Rapid Urease Test for diagnosis of Helicobacter pylori infection. , 2017, Gastroenterologia y hepatologia.

[8]  R. Hunt,et al.  Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report , 2016, Gut.

[9]  G. K. Unler,et al.  A Comparison of Five Different Treatment Regimens as the First‐Line Treatment of Helicobacter pylori in Turkey , 2016, Helicobacter.

[10]  H. B. Tokman,et al.  Prevalence of Primary Antimicrobial Resistance of H. pylori in Turkey: A Systematic Review , 2016, Helicobacter.

[11]  Jason Y. Park,et al.  Helicobacter pylori Clarithromycin Resistance and Treatment Failure Are Common in the USA , 2016, Digestive Diseases and Sciences.

[12]  Deng-Chyang Wu,et al.  Diagnosis of Helicobacter pylori infection: Current options and developments. , 2015, World journal of gastroenterology.

[13]  F. Ermiş,et al.  Current Helicobacter pylori treatment in 2014. , 2015, World journal of methodology.

[14]  Y. Erzin,et al.  Antimicrobial resistance of Helicobacter pylori strains to five antibiotics, including levofloxacin, in Northwestern Turkey. , 2015, Revista da Sociedade Brasileira de Medicina Tropical.

[15]  T. Ayaz,et al.  Comparison of Levofloxacin- and Moxifloxacin-Based Triple Therapies with Standard Treatment in Eradication of Helicobacter Pylori as First-Line Therapy , 2014, Digestion.

[16]  H. Goossens,et al.  Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption , 2012, Gut.

[17]  G. Lee,et al.  Resistance of Helicobacter pylori strains to antibiotics in Korea with a focus on fluoroquinolone resistance , 2012, Journal of gastroenterology and hepatology.

[18]  Nayoung Kim,et al.  Mutations of Helicobacter pylori Associated with Fluoroquinolone Resistance in Korea , 2011, Helicobacter.

[19]  Z. Polat,et al.  Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia. , 2010, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[20]  I. Mitov,et al.  Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents , 2010, Expert review of anti-infective therapy.

[21]  J. Wu,et al.  Prevalence of Primary Fluoroquinolone Resistance Among Clinical Isolates of Helicobacter pylori at a University Hospital in Southern Taiwan , 2009, Helicobacter.

[22]  U. Akarca,et al.  High Helicobacter pylori Resistance Rate to Clarithromycin in Turkey , 2007, Journal of clinical gastroenterology.

[23]  T Rokkas,et al.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report , 2006, Gut.

[24]  M. Kist,et al.  Quinolone Resistance in Helicobacter pylori Isolates in Germany , 2006, Antimicrobial Agents and Chemotherapy.

[25]  Nayoung Kim,et al.  Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients. , 2006, International journal of antimicrobial agents.

[26]  Nayoung Kim,et al.  Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients. , 2005, The Journal of antimicrobial chemotherapy.

[27]  C. O'Morain,et al.  Helicobacter pylori Infection , 1994 .

[28]  M. Osato Antimicrobial susceptibility testing for Helicobacter pylori: sensitivity test results and their clinical relevance. , 2000, Current pharmaceutical design.

[29]  D. Beall Classification and Grading of Gastritis: The Updated Sydney System , 1997 .

[30]  M F Dixon,et al.  Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. , 1996, The American journal of surgical pathology.